Separate routine cervical screening from abnormal-result management, connect HPV biology to dysplasia, and choose surveillance or treatment using patient risk.
A positive HPV result does not mean cervical cancer, and a normal Pap result does not cancel a high-risk HPV genotype. Start by deciding what today’s visit is for. Routine screening, follow-up of an abnormal result, and evaluation of bleeding are three different clinical tasks.
The virus, the tissue, and the basement membrane
Persistent oncogenic HPV infection drives most cervical cancers. Most infections become undetectable within one or two years, so one positive test is not a prediction of inevitable progression. Persistence matters because infected epithelial cells remain exposed to viral proteins that disrupt growth control. Smoking and impaired immunity increase concern for persistence and progression. Do not assign a fixed countdown from infection to invasion to an individual patient. [1]
HPV reaches basal epithelial cells through small epithelial disruptions. The transformation zone is the region where columnar epithelium has been replaced by squamous metaplasia, between the original and current squamocolumnar junctions. This is the key sampling and colposcopic region. High-risk E6 promotes p53 degradation, weakening DNA-damage responses. E7 disrupts retinoblastoma protein control of E2F, permitting cell-cycle progression. HPV 16 and 18 are particularly important oncogenic types; HPV 6 and 11 primarily cause anogenital warts. [1][2]
A koilocyte has perinuclear clearing and an enlarged irregular nucleus. It supports HPV cytopathic change; it does not establish invasion, identify the HPV genotype, or replace risk-based testing. Cytology examines exfoliated cells. Histology examines tissue architecture, including how far abnormal cells extend and whether the basement membrane remains intact. [13]
Read the tissue from the surface toward the supporting stroma
CIN 1
Abnormal immature cells mainly occupy the lower third. Upper layers retain maturation. The basement membrane remains intact.
CIN 2
Abnormal cells extend into roughly the lower two thirds. Maturation is reduced. The basement membrane remains intact.
CIN 3
Severe dysplasia involves more than two thirds, sometimes the full epithelial thickness. The basement membrane remains intact.
Invasive carcinoma
Tumor crosses the basement membrane into stroma. Thickness alone does not establish invasion.
This spatial comparison is schematic. Cytologic LSIL often corresponds to CIN 1; cytologic HSIL often corresponds to CIN 2 or CIN 3. The categories are related, not interchangeable diagnoses. [13]
Choose a screening framework before choosing an interval
Average-risk screening applies to asymptomatic people with a cervix without a history requiring surveillance. The USPSTF final recommendation available at this source check remains the 2018 statement. It recommends cytology every three years at ages 21 to 29. At ages 30 to 65, cytology every three years, primary high-risk HPV testing every five years, or cotesting every five years are accepted. The December 2024 USPSTF update is a draft, not a final replacement. [3][4]
ACS uses a different starting age. Its 2025 update retains primary HPV screening beginning at 25, usually every five years for clinician-collected cervical specimens. FDA-approved self-collected vaginal HPV testing is an acceptable average-risk option; a negative self-collected test generally has a three-year interval. Clinician collection remains preferred. Positive self-collected results may require a return visit for cervical triage or colposcopy. Cytology cannot be performed on a vaginal self-collection as though it were a clinician-collected cervical specimen. [5]
These recommendations can coexist. In a case asking specifically for USPSTF screening at 23, choose cytology. In a case asking for ACS screening at 26, primary HPV testing is appropriate. Do not write a universal rule that primary HPV screening is forbidden before 30. Vaccination, sexual debut, number of partners, and contraceptive use do not independently shorten routine intervals.
Stopping requires a documented history, not just a birthday. Under the USPSTF framework, adequate prior negative screening generally means three negative cytology tests or two negative cotests within ten years, with the latest within five years, and no high-risk reason to continue. The ACS update further specifies exit testing around ages 60 and 65 using its chosen modality. Unknown records do not meet exit criteria. After total hysterectomy for benign disease with no CIN 2+ or cervical cancer history, routine cervical screening is unnecessary. A retained cervix after supracervical hysterectomy still needs screening. [3][5]
HIV requires its own schedule. Current NIH guidance begins cervical screening at 21, not within a year of adolescent sexual debut. Ages 21 to 29 use cytology, initially annually; three consecutive normal annual tests permit a three-year interval. Screening continues beyond 65, guided by health and life expectancy. Do not apply average-risk ACS self-collection or exit rules to this population. Other immunosuppression and prenatal diethylstilbestrol exposure also require condition-specific plans. [6]
Manage the result together with the history
ASCCP management estimates the risk of CIN 3+ from current results and prior HPV-based tests, colposcopy, and treatment. For most patients 25 or older, an immediate CIN 3+ risk of at least 4% reaches the colposcopy threshold. A recent negative HPV test or cotest can lower the risk of a new low-grade abnormality enough for one-year surveillance; a prior negative Pap alone does not provide the same reduction. Use the current ASCCP risk tables or application for combinations beyond these examples. [7]
Common result comparisons
ASC-US with negative HPV and unknown history usually leads to three-year return.
HPV-positive ASC-US or LSIL with unknown history generally leads to colposcopy.
A first non-16/18 high-risk HPV-positive result with NILM cytology usually leads to repeat HPV-based testing in one year under the standard pooled-genotype pathway.
HPV 16 or 18 with NILM warrants colposcopy. Persistent HPV-positive NILM at consecutive annual visits also raises risk enough for colposcopy.
ASC-H requires colposcopy regardless of HPV status. A negative HPV result does not erase concerning cytology.
NILM means negative for intraepithelial lesion or malignancy on cytology. If extended genotyping or dual-stain triage is reported, apply the corresponding Enduring Guidelines pathway rather than forcing the result into a pooled HPV example. Identify the exact assay and triage result before applying a risk estimate. [12]
Patients younger than 25 have a more conservative low-grade pathway. LSIL, HPV-positive ASC-US, or ASC-US without HPV testing leads to repeat cytology at one and two years. High-grade cytology at any point, or low-grade persistence at two years, leads to colposcopy. If reflex HPV for ASC-US is negative, repeat cytology in three years. The younger age group therefore needs its own pathway rather than automatic referral for every positive HPV result. [7]
AGC is not another version of ASC-US. Nonpregnant patients generally need colposcopy and endocervical sampling regardless of HPV. Add endometrial sampling at 35 or older, or earlier with abnormal bleeding, chronic anovulation, obesity, or another endometrial risk. AGC favoring neoplasia or AIS cytology may require diagnostic excision even after an initial evaluation does not find invasion. [7]
Decide what needs tissue and what needs treatment
Colposcopy magnifies the cervix after acetic acid application. Acetowhite change identifies areas to examine and biopsy, but is not specific enough to diagnose cancer by itself. CIN 1 is usually observed. In contrast, CIN 3 is a direct cancer precursor and requires treatment outside pregnancy. Excision, often LEEP, both treats the lesion and supplies tissue for assessing invasion and margins. Hysterectomy is not the primary treatment solely for squamous CIN 3. [7]
CIN 2 is the important exception to “treat every high-grade lesion.” Observation can be acceptable when future pregnancy concerns outweigh cancer concerns, the squamocolumnar junction is fully visible, and endocervical sampling does not show CIN 2+ or ungraded CIN. At 25 or older, observation uses colposcopy and HPV-based testing every six months for up to two years. Persistent CIN 2 for two years requires treatment. In patients younger than 25, observation of CIN 2 is preferred, but CIN 3 still requires treatment. [7][8]
A biopsy is not always required before excision. In nonpregnant patients at least 25, expedited treatment is preferred at an immediate CIN 3+ risk of 60% or more, such as HPV-16-positive HSIL, and acceptable at 25% to below 60%. Discuss the possibility of overtreatment and future pregnancy effects; colposcopy with biopsy remains acceptable. Expedited treatment is not used during pregnancy or below age 25. [9]
Pregnancy changes the procedures, not the need to evaluate possible cancer. Colposcopy and indicated cervical biopsy can be performed. Endocervical curettage and endometrial biopsy are unacceptable during pregnancy. CIN 2 or CIN 3 generally receives surveillance rather than treatment while pregnant; excision is reserved for suspected cancer. Postpartum colposcopy occurs no sooner than four weeks after delivery. [10]
After treatment for CIN 2+, HPV-based tests at 6, 18, and 30 months should be negative before extending to three-year surveillance. Continue surveillance for at least 25 years, even beyond 65 or after hysterectomy when otherwise appropriate. A negative margin or one negative follow-up test does not reset the patient to routine five-year screening. [8]
Prevent new infection and investigate symptoms
Gardasil 9 targets HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58. Routine vaccination is at 11 to 12 and may begin at nine. Catch-up is recommended through 26; ages 27 to 45 use shared decision-making. Starting before 15 usually requires two doses six to twelve months apart. Starting at 15 or later, or being immunocompromised, requires three doses. Vaccination prevents new infections; it does not clear an established lesion. Screening continues after vaccination. [1][11]
Postcoital bleeding, unexplained intermenstrual bleeding, postmenopausal bleeding, persistent watery or bloody discharge, or a friable cervical mass calls for diagnostic evaluation. A screening interval is not permission to wait through symptoms. Examine the cervix and obtain diagnostic tissue when a lesion is suspicious; confirmed invasive disease requires staging and gynecologic oncology care. A recent negative Pap cannot exclude a visible cancer.
At each visit, identify symptoms first, then check whether the cervix is present, whether the patient is in routine screening or surveillance, and which guideline applies. For abnormal results, add age, genotype, cytology, and prior history before choosing an interval or procedure.
Apply the distinctions
Case 1
Show answer and explanations for case 1
A. Repeat cytology in one year (Best answer)
Below 25, ASC-US without HPV testing is followed with cytology at one and two years; HPV triage is not mandatory.
B. Perform immediate colposcopy (Why this does not fit)
This low-grade result does not meet the younger-than-25 indications for immediate colposcopy.
C. Perform LEEP (Why this does not fit)
ASC-US does not establish a high-grade lesion and does not justify excision.
D. Return in five years (Why this does not fit)
Five years is too long for an unresolved abnormal cytology result.
Takeaway: Low-grade abnormalities below 25 use a conservative cytology pathway.
